Breaking new ground: MASLD vs. MAFLD—which holds the key for risk stratification?

Hepatology International, Год журнала: 2023, Номер 18(1), С. 168 - 178

Опубликована: Дек. 21, 2023

Язык: Английский

---

Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspects

European Journal of Preventive Cardiology, Год журнала: 2025, Номер unknown

Опубликована: Фев. 27, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) can be interpreted as the hepatic expression of metabolic syndrome, which is estimated to affect 30% adult population. Obesity, dyslipidaemia, arterial hypertension, and T2DM are considered significant risk factors MASLD. The relationship two-way with MASLD found in up 75% patients T2DM. Importantly, associated increased cardiovascular diseases (CVD) such arrhythmia, atherosclerotic heart disease, failure, CVD-associated mortality. In addition, present a high prevalence major adverse cardiac events, calls for systematic surveillance CVD This review focuses on pathophysiology behind development MASLD, types complications, morbidity survival, suggestions evaluation

Язык: Английский

---

Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease

Hepatoma Research, Год журнала: 2024, Номер 10, С. 16 - 16

Опубликована: Янв. 1, 2024

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic disease. This term does not describe pathogenetic mechanisms and complications associated with NAFLD. The new definition, Metabolic Dysfunction-associated Steatotic Liver (MASLD), emphasizes relationship between NAFLD cardiometabolic comorbidities. Cardiovascular features, such as arterial hypertension atherosclerosis, are frequently patients MASLD. Furthermore, these have a high risk developing neoplastic diseases, primarily hepatocellular carcinoma, but also extrahepatic tumors, esophageal, gastric, pancreatic cancers. Moreover, several studies showed correlation MASLD endocrine imbalance gut microbiota, systemic inflammation, obesity, insulin resistance play key role in development complications. narrative review aims to clarify evolution from nomenclature evaluate its

Язык: Английский

---

Thyme, oregano, and rosemary: herbs and food supplements for the management of metabolic associated fatty liver disease

Nutrire, Год журнала: 2025, Номер 50(1)

Опубликована: Янв. 6, 2025

Язык: Английский

---

Nicotinamide Adenine Dinucleotide Phosphate Oxidases and Metabolic Dysfunction-Associated Steatotic Liver Disease

Antioxidants, Год журнала: 2025, Номер 14(1), С. 83 - 83

Опубликована: Янв. 13, 2025

Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by lipid accumulation in the due to an excess their supplies or impairment management. While some patients remain stable for years, a proportion of them progress up steatohepatitis (MASH). MASLD links with systemic pathways being associated metabolic and non-metabolic diseases. Although represents first hit MASLD, pathophysiology its development progression MASH remains not completely understood. Oxidative stress has received particular attention recent as most oxidative process occurs liver, which also target stress-induced damage. Growing evidence linked activity nicotinamide adenine dinucleotide phosphate (NADPH) oxidases (NOX) increased production reactive oxygen species damage fibrosis. NOX acts both hepatocytes non-parenchymal hepatic cells, contributing hepatocyte lipotoxicity, impaired microcirculation, stellate, mesenchymal stem cells activation proliferation. This review aims summarize current knowledge on involvement MASLD-MASH transition, focusing role isoforms, suggest targeting therapeutic approach MASLD.

Язык: Английский

---

Golgi protein 73: charting new territories in diagnosing significant fibrosis in MASLD: a prospective cross-sectional study

Frontiers in Endocrinology, Год журнала: 2025, Номер 15

Опубликована: Янв. 13, 2025

To explore the correlation between serum Golgi protein 73 (GP73) levels and degree of fibrosis in Metabolic dysfunction associated steatotic liver disease (MASLD); to establish a non-invasive diagnostic algorithm based on GP73 elasticity. This is prospective cross-sectional study, including 228 patients diagnosed with MASLD from May 2018 January 2024 at two tertiary hospitals. Clinical data hepatic pathological features were assessed. A new was conducted after logistic regression. Receiver Operating Characteristic (ROC) curve used compare its performance traditional models. Significant 37.2% (85/228) patients. Serum markedly higher significant than those without (128 ng/mL v.s 46 ng/mL, p< 0.001). independently predicted (adjusted odds ratio, aOR 1.028, developed area under ROC (AUC) 0.840 that Fibrosis index-4 (p< an independent risk factor for MASLD, GFA (GP73-Fibroscan-Age) model has good efficacy fibrosis.

Язык: Английский

---

Impact of microplastics and nanoplastics on liver health: Current understanding and future research directions

World Journal of Gastroenterology, Год журнала: 2024, Номер 30(9), С. 1011 - 1017

Опубликована: Март 5, 2024

With continuous population and economic growth in the 21

Язык: Английский

---

Prebiotic Treatment in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)—A Randomized Pilot Trial

Nutrients, Год журнала: 2024, Номер 16(11), С. 1571 - 1571

Опубликована: Май 22, 2024

Several studies show that gut microbiotas in patients with nonalcoholic fatty liver disease (NAFLD) differ from those a healthy population, suggesting this alteration plays role NAFLD pathogenesis. We investigated whether prebiotic administration affects fat content and/or liver-related and metabolic parameters. Patients syndrome (age: 50 ± 11; 79% men) were randomized to receive either 16 g/day of (ITFs-inulin-type fructans) (n = 8) or placebo (maltodextrin) 11) for 12 weeks. instructed maintain stable weight throughout the study. Liver (measured by H1MRS), fecal microbiota, metabolic, inflammatory, parameters determined before after intervention. Fecal samples who received had an increased Bifidobacterium (p 0.025), which was not observed placebo. However, baseline end-of-study contents did change significantly groups, neither function tests' inflammatory mediators, including fibroblast growth factor-19 lipopolysaccharide-binding protein. Body remained both groups. These findings suggest treatment without reduction is insufficient improve NAFLD.

Язык: Английский

---

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis

Annals of Hepatology, Год журнала: 2023, Номер 29(2), С. 101174 - 101174

Опубликована: Окт. 29, 2023

Nonalcoholic fatty liver disease (NAFLD) is a chronic with high prevalence worldwide and poses serious harm to human health. There growing evidence suggesting that the administration of specific supplements or nutrients may slow NAFLD progression. Silymarin hepatoprotective extract milk thistle, but its efficacy in remains unclear. Relevant studies were searched PubMed, Embase, Cochrane Library, Web Science, clinicaltrails.gov, China National Knowledge Infrastructure screened according eligibility criteria. Data analyzed using Revman 5.3. Continuous values dichotomous pooled standard mean difference (SMD) odds ratio (OR). Heterogeneity was evaluated Cochran's Q test (I2 statistic). A P<0.05 considered statistically significant. total 26 randomized controlled trials involving 2,375 patients included this study. Administration silymarin significantly reduced levels TC (SMD[95%CI]=-0.85[-1.23, -0.47]), TG (SMD[95%CI]=-0.62[-1.14, -0.10]), LDL-C (SMD[95%CI]=-0.81[-1.31, -0.31]), FI (SMD[95%CI]=-0.59[-0.91, -0.28]) HOMA-IR (SMD[95%CI]=-0.37[-0.77, 0.04]), increased level HDL-C (SMD[95%CI]=0.46[0.03, 0.89]). In addition, attenuated injury as indicated by decreased ALT (SMD[95%CI]=-12.39[-19.69, -5.08]) AST (SMD[95% CI]=-10.97[-15.51, -6.43]). The index (SMD[95%CI]=-6.64[-10.59, -2.69]) score (SMD[95%CI]=-0.51[-0.69, -0.33]) also decreased. Liver histology intervention group revealed improved hepatic steatosis (OR[95%CI]=3.25[1.80, 5.87]). can regulate energy metabolism, attenuate damage, improve patients. However, effects will need be confirmed further research.

Язык: Английский

---

Metabolic dysfunction associated fatty liver disease in healthy weight individuals

Hepatology International, Год журнала: 2024, Номер 18(S2), С. 884 - 896

Опубликована: Июль 25, 2024

Metabolic dysfunction associated fatty liver disease (MAFLD) is an increasing public health problem, affecting one third of the global population. Contrary to conventional wisdom, MAFLD not exclusive obese or overweight individuals. Epidemiological studies have revealed a remarkable prevalence among healthy weight individuals, leading investigations into genetic, lifestyle, and dietary factors that contribute development in this This shift perspective requires reconsideration preventive strategies, diagnostic criteria therapeutic approaches tailored address unique characteristics It also underscores importance widespread awareness education, within medical community general population, promote more inclusive understanding metabolic disorders. With review, we aim provide comprehensive exploration encompassing epidemiological, pathophysiological, clinical aspects.

Язык: Английский

---